ECSP16096826A - Formulación de Ceritinib - Google Patents

Formulación de Ceritinib

Info

Publication number
ECSP16096826A
ECSP16096826A ECIEPI201696826A ECPI201696826A ECSP16096826A EC SP16096826 A ECSP16096826 A EC SP16096826A EC IEPI201696826 A ECIEPI201696826 A EC IEPI201696826A EC PI201696826 A ECPI201696826 A EC PI201696826A EC SP16096826 A ECSP16096826 A EC SP16096826A
Authority
EC
Ecuador
Prior art keywords
ceritinib
alk
dose
approved
phenyl
Prior art date
Application number
ECIEPI201696826A
Other languages
English (en)
Inventor
Breulles Sebastien
Ensslin Simon
Original Assignee
Productos Familia Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53298568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP16096826(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Productos Familia Sa filed Critical Productos Familia Sa
Publication of ECSP16096826A publication Critical patent/ECSP16096826A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

WO2008/073687 A1 describe ceritinib (también llamado LDK378) como el compuesto 66 en el Ejemplo 7. La fórmula química de ceritinib es 5-cloro-N2 -(2-isopropoxi-5-metil-4-(piperidin-4-il)fenil)-N4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina. Ceritinib es un inhibidor de la quinasa del linfoma anaplástico (ALK). ALK es un miembro de la superfamilia del receptor de insulina de las tirosina quinasas receptoras. Las alteraciones genéticas de ALK han sido implicadas en la oncogénesis en tumores hematopoyéticos y no hematopoyéticos. Se encontró que el gen se ha reordenado, mutado, o amplificado en una serie de tumores, que incluyen cáncer de pulmón de células no pequeñas. El Ceritinib ha sido aprobado por la FDA de EE.UU. como Zykadia® para el tratamiento de pacientes con cáncer de pulmón de células no pequeñas (NSCLC) metastásico ALK positivo quienes han progresado o no toleran el crizotinib. La dosis aprobada es una dosis diaria de 750 mg administrada por vía oral, con una posible reducción de dosid en incrementos de 150 mg a 600 mg y 450 mg según sea necesario. La dosis de tratamiento mínima es de 300mg. La forma de dosificación aprobada es una cápsula de tamaño 00 que contiene una dosis de 150 mg de ceritinib.
ECIEPI201696826A 2014-05-29 2016-12-28 Formulación de Ceritinib ECSP16096826A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462004359P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
ECSP16096826A true ECSP16096826A (es) 2018-04-30

Family

ID=53298568

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201696826A ECSP16096826A (es) 2014-05-29 2016-12-28 Formulación de Ceritinib

Country Status (27)

Country Link
US (4) US20170112834A1 (es)
EP (1) EP3148513B1 (es)
JP (3) JP6679578B2 (es)
KR (1) KR20170008239A (es)
CN (1) CN106456640B (es)
AR (1) AR100625A1 (es)
AU (3) AU2015265470A1 (es)
BR (1) BR112016027580A8 (es)
CA (1) CA2948291A1 (es)
CL (1) CL2016003047A1 (es)
DK (1) DK3148513T3 (es)
EA (1) EA036922B1 (es)
EC (1) ECSP16096826A (es)
ES (1) ES2792574T3 (es)
HU (1) HUE048950T2 (es)
IL (1) IL248835B (es)
MX (1) MX373624B (es)
PE (1) PE20170313A1 (es)
PH (1) PH12016502272A1 (es)
PL (1) PL3148513T3 (es)
PT (1) PT3148513T (es)
SG (1) SG11201609208UA (es)
SI (1) SI3148513T1 (es)
TN (1) TN2016000484A1 (es)
TW (1) TWI721946B (es)
UY (1) UY36140A (es)
WO (1) WO2015181739A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation
CN106176752B (zh) * 2015-05-07 2020-06-23 石药集团中奇制药技术（石家庄）有限公司 色瑞替尼药物组合物
CN109381440A (zh) * 2018-11-15 2019-02-26 威海贯标信息科技有限公司 一种艾乐替尼组合物
CN113244236B (zh) * 2021-06-01 2023-02-03 上海市第一人民医院 色瑞替尼在制备治疗甲状腺相关眼病的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
PE20071315A1 (es) * 2006-03-06 2008-02-14 Wyeth Corp Formulaciones de compuestos derivados de fenilo y procesos de preparacion para tabletas que contienen dichos compuestos
US20090239920A1 (en) 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
BRPI0722383A2 (pt) * 2006-12-08 2012-06-05 Irm Llc compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
SI2334202T1 (sl) 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
BR112012003631A2 (pt) 2009-08-18 2015-09-01 Gargill Inc "produção de comprimidos de eritritol e isomalte."
JP5596799B2 (ja) 2010-05-11 2014-09-24 田辺三菱製薬株式会社 カナグリフロジン含有錠剤
JP2013536694A (ja) 2010-09-07 2013-09-26 カーギル インコーポレイテッド 凝固糖アルコール混合物
AU2015265470A1 (en) 2014-05-29 2016-11-24 Novartis Ag Ceritinib formulation

Also Published As

Publication number Publication date
US20200009141A1 (en) 2020-01-09
AU2018203007B2 (en) 2019-07-18
CN106456640B (zh) 2021-05-14
US11000523B2 (en) 2021-05-11
JP2022078236A (ja) 2022-05-24
JP2020114834A (ja) 2020-07-30
IL248835B (en) 2020-05-31
TW201613580A (en) 2016-04-16
PT3148513T (pt) 2020-05-27
MX373624B (es) 2020-05-22
CL2016003047A1 (es) 2017-04-07
BR112016027580A8 (pt) 2021-06-29
DK3148513T3 (da) 2020-05-25
US20210154194A1 (en) 2021-05-27
HUE048950T2 (hu) 2020-09-28
JP2017520619A (ja) 2017-07-27
PE20170313A1 (es) 2017-04-18
WO2015181739A1 (en) 2015-12-03
EP3148513A1 (en) 2017-04-05
EA201692310A1 (ru) 2017-04-28
AU2018203007A1 (en) 2018-05-17
PL3148513T3 (pl) 2020-08-24
AR100625A1 (es) 2016-10-19
EA036922B1 (ru) 2021-01-15
AU2019232937B2 (en) 2020-10-15
KR20170008239A (ko) 2017-01-23
BR112016027580A2 (pt) 2017-08-15
MX2016015736A (es) 2017-03-16
AU2015265470A1 (en) 2016-11-24
US20190022095A1 (en) 2019-01-24
SI3148513T1 (sl) 2020-07-31
ES2792574T3 (es) 2020-11-11
US12357630B2 (en) 2025-07-15
UY36140A (es) 2016-01-08
SG11201609208UA (en) 2016-12-29
JP7084955B2 (ja) 2022-06-15
PH12016502272A1 (en) 2017-02-06
US20170112834A1 (en) 2017-04-27
CN106456640A (zh) 2017-02-22
TN2016000484A1 (en) 2018-04-04
CA2948291A1 (en) 2015-12-03
IL248835A0 (en) 2017-01-31
EP3148513B1 (en) 2020-02-26
TWI721946B (zh) 2021-03-21
AU2019232937A1 (en) 2019-10-10
JP6679578B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
Deng et al. Targeting the DNA damage response and DNA repair pathways to enhance radiosensitivity in colorectal cancer
CN103458881B (zh) Alk抑制剂的使用方法
JP2016521280A5 (es)
NZ736048A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
MX2010003668A (es) Derivados de purina sustituidas con primidina.
NZ604480A (en) Morpholino pyrimidines and their use in therapy
JP2016533366A5 (es)
PH12014501992A1 (en) Macrocyclic derivatives for the treatment of proliferative diseases
CU20130133A7 (es) Sales de 2,3- dihidroimidazo[1,2- c] quinazolinas sustituda
ECSP109935A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
PE20190390A1 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
JP2014532704A5 (es)
JP2016529285A5 (es)
CL2016000816A1 (es) Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras.
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
CL2008002880A1 (es) (s)-2-amino-3-(4-(2-amino-6-((r-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoato de etilo cristalino, sal hipurato y succionato del mismo; metodos de preparacion; forma de dosificacion farmaceutica; y uso para tratar sindrome carcinoide y trastorno gastrointestinal.
NZ741615A (en) Treatment of brain cancer
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
UY34076A (es) Composición farmacéutica que contiene volasertib en dosificación mejorada y sus usos contra tumores sólidos avanzados
RU2016110874A (ru) Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний
WO2018136009A1 (en) Combination therapy
GB201302704D0 (en) Therapeutic compounds
WO2018136010A1 (en) Combination therapy
PH12017502252A1 (en) Stable pharmaceutical composition for oral administration